Vir to Reduce Operating Expenses and Focus Areas with Highest Potential for Value Creation

 Reinforcing strategic focus on chronic hepatitis delta and chronic hepatitis B clinical programs and antibody platform to target infectious diseases, autoimmune diseases, and oncology –

– Reducing workforce by approximately 12% and consolidating geographic footprint –

– Anticipate annual savings of at least $40 million from cost optimization efforts –

https://www.businesswire.com/news/home/20231213396441/en/